Lancet neurology
The most recent articles from:
Lancet Neurol
-
Letter Biography Historical Article
Unique drawings by Duchenne de Boulogne.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
IPX066 is an oral, extended-release, capsule formulation of carbidopa-levodopa. We aimed to assess this extended-release formulation versus immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations. ⋯ Impax Laboratories.
-
Randomized Controlled Trial Multicenter Study
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival. We aimed to assess whether lithium improves survival in patients with ALS. ⋯ The Motor Neurone Disease Association of Great Britain and Northern Ireland.